Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Fig. 1

Baseline levels of serum cytokines (IL-10, TNFα, and IFNγ), Th17 effector cytokines (IL-17A, IL-17F, and IL-22) and acute phase proteins (CRP, SAA, and IL-6) in participants with TNFi-IR PsA from COSMOS and in healthy controls. *p < 0.001 TNFi-IR PsA versus HCs; †p < 0.05 TNFi-IR PsA versus HCs. CRP, C-reactive protein; HC, healthy control; IFN, interferon; IL, interleukin; PsA, psoriatic arthritis; SAA, serum amyloid A; SD, standard deviation; Th17, T helper 17; TNF, tumor necrosis factor; TNFi-IR, tumor necrosis factor inhibitor inadequate response

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us